Abstract
Neuropathy is a common complication of diabetes mellitus, which reduces the quality of life and may be lifethreatening. The etiology is complex and multifactorial: hyperglycemia and dyslipidemia give rise to oxidative stress and formation of advanced glycation and lipoxidation end products. These stimulate inflammatory processes, nuclear factor κ B (NFκB) activation being of central importance. Many of the drugs that have been developed for treatment of diabetic complication at least in part work through suppressing either NFκB activation itself, or the production of cytokines that stimulate NFκB, such as tumor necrosis factor (TNF) α. To date there have been few tests of drugs that are specific inhibitors of the NFκB / TNFα axis. However preliminary results in animal models are encouraging and go some way in establishing the NFκB cascade as an important therapeutic target for diabetic vascular complications in general, and neuropathy in particular.
Keywords: p38 MAPK inhibitors, COX 2, nuclear peroxisome proliferator activated receptor, nerve conduction velocity, I kappa B kinase 2
Current Drug Targets
Title: Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Volume: 9 Issue: 1
Author(s): Norman E. Cameron and Mary A. Cotter
Affiliation:
Keywords: p38 MAPK inhibitors, COX 2, nuclear peroxisome proliferator activated receptor, nerve conduction velocity, I kappa B kinase 2
Abstract: Neuropathy is a common complication of diabetes mellitus, which reduces the quality of life and may be lifethreatening. The etiology is complex and multifactorial: hyperglycemia and dyslipidemia give rise to oxidative stress and formation of advanced glycation and lipoxidation end products. These stimulate inflammatory processes, nuclear factor κ B (NFκB) activation being of central importance. Many of the drugs that have been developed for treatment of diabetic complication at least in part work through suppressing either NFκB activation itself, or the production of cytokines that stimulate NFκB, such as tumor necrosis factor (TNF) α. To date there have been few tests of drugs that are specific inhibitors of the NFκB / TNFα axis. However preliminary results in animal models are encouraging and go some way in establishing the NFκB cascade as an important therapeutic target for diabetic vascular complications in general, and neuropathy in particular.
Export Options
About this article
Cite this article as:
Cameron E. Norman and Cotter A. Mary, Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway, Current Drug Targets 2008; 9 (1) . https://dx.doi.org/10.2174/138945008783431718
DOI https://dx.doi.org/10.2174/138945008783431718 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
P2X Receptors and Diabetes
Current Medicinal Chemistry The Treatment of Painful Diabetic Neuropathy
Current Diabetes Reviews Role and Treatment of Mitochondrial DNA-Related Mitochondrial Dysfunction in Sporadic Neurodegenerative Diseases
Current Pharmaceutical Design Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes
Current Diabetes Reviews Exploiting High-Throughput Ion Channel Screening Technologies in Integrated Drug Discovery
Current Pharmaceutical Design Diabetic Complications and Insight into Antidiabetic Potentialities of Ethno- Medicinal Plants: A Review
Recent Patents on Inflammation & Allergy Drug Discovery The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics Systemic Inflammation, Infection, ApoE Alleles, and Alzheimer Disease: A Position Paper
Current Alzheimer Research Depression and Quality of Life in Patients with Diabetes: A Systematic Review from the European Depression in Diabetes (EDID) Research Consortium
Current Diabetes Reviews Assessing Cardiovascular Risk in Patients with Diabetes: An Update
Current Cardiology Reviews Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Meet Our Editorial Board Member:
Current Medicinal Chemistry Deep Venous Thrombosis Associated with Thalidomide use in a Case of Steroid Dependent Erythema Nodosum Leprosum-a Management Conundrum
Current Drug Safety Perspective of Molecular Hydrogen in the Treatment of Sepsis
Current Pharmaceutical Design Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes
Current Pharmaceutical Design An Overview of the Actions of Capsaicin and Its Receptor, TRPV1, and Their Relations to Small Primary Sensory Neurons
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Potential Role of Angiotensin Converting Enzyme and Vasopeptidase Inhibitors in the Treatment of Diabetic Neuropathy
Current Drug Targets Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry